Business Context and Reporting Period
Company: A.P. Pharma, Inc. (Note: Metadata referenced "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: A specialty pharmaceutical company focused on developing products using proprietary Biochronomer polymer-based drug delivery technology. The primary focus is the lead product candidate APF530 (for chemotherapy-induced nausea and vomiting), for which a New Drug Application (NDA) was submitted to the FDA in May 2009 with an action date of March 18, 2010. Other pipeline products have been deferred to focus resources on APF530.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2008 |
|---|---|---|---|
| Contract Revenue | $1,117 | $1,139 | $348 |
| Operating Expenses | $2,330 | $9,281 | $19,962 |
| Net Loss | $(1,214) | $(8,115) | $(19,179) |
| Cash and Cash Equivalents (End of Period) | $1,569 | $1,569 | $15,680 |
| Working Capital | $(91) | $(91) | N/A |
| Stockholders' Equity | $482 | $482 | N/A |
Liquidity: As of September 30, 2009, the company held $1.6 million in cash and cash equivalents and marketable securities. The company reported negative working capital of $0.1 million.
Material Changes vs. Prior Period
- Revenue Increase: Contract revenue for the nine months ended September 30, 2009, increased to $1.1 million from $0.3 million in the prior year period. This increase was primarily driven by the recognition of $1.0 million in previously deferred revenue following the termination of an agreement with RHEI Pharmaceuticals in September 2009.
- Expense Reduction: Research and development (R&D) expenses decreased significantly to $6.4 million for the nine months ended September 30, 2009, compared to $16.7 million in the prior year. This reduction is attributed to the completion of the Phase III trial for APF530, the deferral of other product candidates, and workforce reductions in late 2008 and May 2009.
- Cash Burn: Net cash used in operating activities decreased to $9.0 million for the nine months ended September 30, 2009, compared to $18.2 million in the prior year, reflecting the reduced net loss and changes in working capital.
- Balance Sheet Deterioration: Total assets declined from $11.8 million at December 31, 2008, to $3.0 million at September 30, 2009, primarily due to the drawdown of cash and marketable securities to fund operations.
Guidance, Outlook, and Risks
- Regulatory Outlook: The FDA has issued an action date of March 18, 2010, for the APF530 NDA. Management anticipates contract revenues to increase in the near term following a new licensing agreement with Merial Limited for a long-acting pain management product for animals.
- Subsequent Financing: In October 2009 (subsequent to the reporting period), the company completed a private placement raising approximately $8.1 million. Management believes this financing enables the company to fund operations through 2010 and meet NASDAQ Capital Market listing requirements.
- Listing Risks: The company received notice from NASDAQ regarding non-compliance with the $1.00 minimum bid price requirement. A grace period was granted until March 15, 2010, to regain compliance. Failure to comply could result in delisting.
- Contingencies: A liability of $621,000 remains accrued for a gross profit guarantee related to a discontinued cosmeceutical business sold in 2000. The company has not paid amounts asserted by the successor company (Amcol) pending documentation of costs.
Investor Verification Checklist
- APF530 Approval Status: Verify the FDA's decision on the APF530 NDA by the March 18, 2010 action date, as commercialization depends on this approval.
- Post-Financing Liquidity: Confirm the utilization of the $8.1 million raised in October 2009 and whether it has stabilized the balance sheet to meet NASDAQ equity requirements ($2.5 million).
- NASDAQ Compliance: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by the March 15, 2010 deadline to avoid delisting.
- RHEI Termination: Confirm that the $1.0 million revenue recognized from the RHEI termination was fully collected and that no further legal disputes exist regarding the agreement.
- Merial Agreement Milestones: Track the progress of the new agreement with Merial Limited to ensure anticipated development funding and milestone payments are realized.